Skip to content
2000
Volume 21, Issue 9
  • ISSN: 1573-4064
  • E-ISSN: 1875-6638

Abstract

Background

Neurodegenerative diseases are a group of disorders characterized by progressive neuronal degeneration and death, of which Alzheimer's disease and Parkinson's disease are the most common. These diseases are closely associated with increased expression of monoamine oxidase B (MAO-B), an important enzyme that regulates neurotransmitter concentration, and its overactivity leads to oxidative stress and neurotoxicity, accelerating the progression of neurodegenerative diseases. Therefore, the development of effective MAO-B inhibitors is important for the treatment of neurodegenerative diseases.

Objective

This study aims to improve the prediction of the efficacy of novel 6-hydroxy-benzothiazole-2-carboxamide compounds in inhibiting MAO-B by improving the quantitative constitutive effect relationship (QSAR) modeling and to provide a theoretical basis for the discovery of novel neuroprotective drugs.

Methods

The study first optimized the structures of 36 compounds using the heuristic method (HM) in CODESSA software to construct linear QSAR models. Subsequently, key descriptors were screened by using the gene expression programming (GEP) technique to generate nonlinear QSAR models and validate them.

Results

The R2, F-value, and R2cv of the linear model were 0.5724, 10.3752, and 0.4557, respectively, whereas the nonlinear model constructed by the GEP algorithm showed higher prediction accuracies by achieving R2 values of 0.89 and 0.82, and mean squared errors (MSE) of 0.0799 and 0.1215 for the training and test sets, respectively. In addition, molecular docking experiments confirmed that the novel compound 31 was tightly bound to the MAO-B active site with significant inhibitory activity.

Conclusion

In this study, we successfully improved the prediction ability of the efficacy of novel 6-hydroxybenzothiazole-2-carboxamide compounds to inhibit MAO-B by improving the QSAR model. This not only provides new drug candidates for the treatment of neurodegenerative diseases, but also provides important theoretical guidance for subsequent drug design and development, which can help accelerate the process of new drug discovery and reduce the disease burden of patients.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/mc/10.2174/0115734064364749250102024805
2025-01-20
2025-12-01

  • From This Site

    /content/journals/mc/10.2174/0115734064364749250102024805
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. CherietM. DentamaroV. HamdanM. ImpedovoD. PirloG. Multi-speed transformer network for neurodegenerative disease assessment and activity recognition.Comput. Methods Programs Biomed.202323010734410.1016/j.cmpb.2023.107344 36706617
     [Google Scholar]
  2. WilsonD.M. III. CooksonM.R. Van Den BoschL. ZetterbergH. HoltzmanD.M. DewachterI. Hallmarks of neurodegenerative diseases.Cell2023186469371410.1016/j.cell.2022.12.032 36803602
     [Google Scholar]
  3. NandiA. CountsN. ChenS. SeligmanB. TortoriceD. VigoD. BloomD.E. Global and regional projections of the economic burden of Alzheimer’s disease and related dementias from 2019 to 2050: A value of statistical life approach. EClin.Med.20225110158010.1016/j.eclinm.2022.101580 35898316
     [Google Scholar]
  4. ScheltensP. De StrooperB. KivipeltoM. HolstegeH. ChételatG. TeunissenC.E. CummingsJ. van der FlierW.M. Alzheimer’s disease.Lancet2021397102841577159010.1016/S0140‑6736(20)32205‑4 33667416
     [Google Scholar]
  5. BloemB.R. OkunM.S. KleinC. Parkinson’s disease.Lancet2021397102912284230310.1016/S0140‑6736(21)00218‑X 33848468
     [Google Scholar]
  6. Schedin-WeissS. InoueM. HromadkovaL. TeranishiY. YamamotoN.G. WiehagerB. BogdanovicN. WinbladB. Sandebring-MattonA. FrykmanS. TjernbergL.O. Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels.Alzheimers Res. Ther.2017915710.1186/s13195‑017‑0279‑1 28764767
     [Google Scholar]
  7. Bhawna KumarA. BhatiaM. KapoorA. KumarP. KumarS. Monoamine oxidase inhibitors: A concise review with special emphasis on structure activity relationship studies.Eur. J. Med. Chem.202224211465510.1016/j.ejmech.2022.114655 36037788
     [Google Scholar]
  8. ÖzdemirZ. AlagözM.A. BahçecioğluÖ.F. GökS. Monoamine oxidase-B (MAO-B) inhibitors in the treatment of Alzheimers and Parkinsons disease.Curr. Med. Chem.202128296045606510.2174/1875533XMTEzjOTQcw 33538661
     [Google Scholar]
  9. MathewB. OhJ.M. ParambiD.G.T. SudevanS.T. KumarS. KimH. Enzyme inhibition assays for monoamine oxidase.Methods Mol. Biol.2024276132933610.1007/978‑1‑0716‑3662‑6_24 38427248
     [Google Scholar]
  10. MüllerT. MöhrJ.D. Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson’s disease: Current status.Expert Opin. Drug Metab. Toxicol.201915542943510.1080/17425255.2019.1607292 31017021
     [Google Scholar]
  11. TropshaA. IsayevO. VarnekA. SchneiderG. CherkasovA. Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR.Nat. Rev. Drug Discov.202423214115510.1038/s41573‑023‑00832‑0 38066301
     [Google Scholar]
  12. ConcuR. González-DurruthyM. CordeiroM.N.D.S. Developing a multi-target model to predict the activity of monoamine oxidase A and B drugs.Curr. Top. Med. Chem.202020181593160010.2174/1568026620666200603121224 32493193
     [Google Scholar]
  13. PutriI.S. ShamsudinN.F. AbdullahM.A. NurcholisM. ImranS. YuC.X. ThamC.L. Mohd AluwiM.F.F. LeongS.W. Joko RaharjoS. IbrahimZ. IslamiD. HuqA.M. TaherM. RullahK. Theoretical investigation of selective inhibitory activity of chromone-based compounds against monoamine oxidase (MAO)-A and -B.J. Biomol. Struct. Dyn.202411810.1080/07391102.2024.2436553 39633610
     [Google Scholar]
  14. Al-SaadO.M. GabrM. DarwishS.S. RulloM. PisaniL. MinieroD.V. LiuzziG.M. KanyA.M. HirschA.K.H. AbadiA.H. EngelM. CattoM. Abdel-HalimM. Novel 6-hydroxybenzothiazol-2-carboxamides as potent and selective monoamine oxidase B inhibitors endowed with neuroprotective activity.Eur. J. Med. Chem.202426911626610.1016/j.ejmech.2024.116266 38490063
     [Google Scholar]
  15. FroimowitzM. HyperChem: a software package for computational chemistry and molecular modeling.Biotechniques199314610101013 8333944
     [Google Scholar]
  16. MayenoA.N. RobinsonJ.L. YangR.S.H. ReisfeldB. Predicting activation enthalpies of cytochrome-P450-mediated hydrogen abstractions. 2. Comparison of semiempirical PM3, SAM1, and AM1 with a density functional theory method.J. Chem. Inf. Model.20094971692170310.1021/ci8003946 19522482
     [Google Scholar]
  17. KatritzkyA.R. PetrukhinR. JainR. KarelsonM. QSPR analysis of flash points.J. Chem. Inf. Comput. Sci.20014161521153010.1021/ci010043e 11749578
     [Google Scholar]
  18. SiH. ZhaoJ. CuiL. LianN. FengH. DuanY.B. HuZ. Study of human dopamine sulfotransferases based on gene expression programming.Chem. Biol. Drug Des.201178337037710.1111/j.1747‑0285.2011.01155.x 21668651
     [Google Scholar]
  19. PopeS.D. MedzhitovR. Emerging principles of gene expression programs and their regulation.Mol. Cell201871338939710.1016/j.molcel.2018.07.017 30075140
     [Google Scholar]
  20. ZhangL. HanL. WangX. WeiY. ZhengJ. ZhaoL. TongX. Exploring the mechanisms underlying the therapeutic effect of Salvia miltiorrhiza in diabetic nephropathy using network pharmacology and molecular docking.Biosci. Rep.2021416BSR2020352010.1042/BSR20203520 33634308
     [Google Scholar]
  21. MoulishankarA. ThirugnanasambandamS. Quantitative structure activity relationship (QSAR) modeling study of some novel thiazolidine 4-one derivatives as potent anti-tubercular agents.J. Recept. Signal Transduct. Res.2023433839210.1080/10799893.2023.2281671 37990804
     [Google Scholar]
  22. ChenY. MaK. XuP. SiH. DuanY. ZhaiH. Design and screening of new lead compounds for autism based on qsar model and molecular docking studies.Molecules20222721728510.3390/molecules27217285 36364109
     [Google Scholar]
  23. De NuccioF. KashyrinaM. SerinelliF. LaferrièreF. LofrumentoD.D. De GiorgiF. IchasF. Oligodendrocytes prune axons containing α-synuclein aggregates in vivo: Lewy neurites as precursors of glial cytoplasmic inclusions in multiple system atrophy?Biomolecules202313226910.3390/biom13020269 36830639
     [Google Scholar]
  24. NaoiM. MaruyamaW. Shamoto-NagaiM. RiedererP. Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson’s disease.J. Neural Transm.2024131663966110.1007/s00702‑023‑02730‑6 38196001
     [Google Scholar]
/content/journals/mc/10.2174/0115734064364749250102024805
Loading
High-prediction QSAR Modeling Study Based on the Efficacy of a Novel 6-hydroxybenzothiazole-2-carboxamide Targeted Monoamine Oxidase B in the Treatment of Neurodegenerative Diseases
Med. Chem. 21, 1008 (2025); https://doi.org/10.2174/0115734064364749250102024805
/content/journals/mc/10.2174/0115734064364749250102024805
/content/journals/mc/10.2174/0115734064364749250102024805
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): 6-hydroxybenzothiazole-2-carboxamide; GEP; HM; MAO-B; neuroprotective activity; QSAR

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test